"AlloVir and Kalaris enter merger to advance retinal disease therapies" was originally created and published by ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Shares of AlloVir (NASDAQ:ALVR) lost ~18% in the premarket on Friday after the cell therapy developer announced an all-stock merger agreement with clinical-stage biopharmaceutical company Kalaris ...

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related ...

AlloVir (ALVR) announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

Shares of AlloVir tumbled in premarket trading Friday after the immunotherapy company said it has agreed to an all-stock reverse merger with clinical-stage biopharmaceutical company Kalaris ...

Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn how to join our investigation ...

Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn how to join our ...

and PALO ALTO, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR) today announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics ...